Back to Agenda
Value Proposition, Challenges and Examples for the Use of Big Data in the Pharmaceutical Industry
Session Chair(s)
Duane Schulthess, MBA
Chief Executive Officer
Vital Transformation LLC, United States
Whilst the term “Big Data” runs the risk of becoming a hackneyed cliché, the fact remains that harnessing multiple large data sets and tapping into real world evidence has the potential to provide one of the largest leaps forward in bringing new therapies to market since the development of the randomised clinical trial. However, simply saying the words “Big Data” loudly is not enough; what are actual examples of how to use these datasets to create new sources of evidence, improve targeting of patient segmentations, and create a better understanding of value for HTA? Further, what are the pitfalls of Big Data, and how do we avoid falling down a bottomless pit of rhetorical and analytical excess?
Speaker(s)
Challenges and Opportunities of Big Data for Observational Studies on Drug Safety and Effectiveness
Olaf Klungel, MPharm
Utrecht University, Faculty of Science, Netherlands
Professor of Pharmacoepidemiologic Methods
Protocol Optimisation through Clinical Big Data: possibilities and constraints
Isabelle de Zegher, DrMed, MD, MS, MSc
b!loba, Belgium
Founder
Analytical Challenges of Big Data
Michael Hennig
GlaxoSmithKline Gmbh & Co. KG, Germany
Head of Biostatistics & Epidemiology
Have an account?